Navamedic ASA (0FDB) Share Price & Analysis

0FDB Stock Chart & Stats

NOK 11.20NOK 1.20(12.00%)

At close: Oct 30 4:30 PM GMT

Day’s Range: NOK 11.20 - NOK 11.35
52-Week Range: NOK 10.00 - NOK 26.50
Previous Close: NOK 10.00
Volume: 0
Average Volume (3M): 78
Market Cap: NOK 267.39M
Enterprise Value: NOK 463.99M
Total Cash (Recent Filing): NOK 53.48M
Total Debt (Recent Filing): NOK 139.93M
Price to Earnings (P/E): ―
Beta: -0.02
Next Earnings: Feb 12, 2027 (Est.)
EPS Estimate: 0.01
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Navamedic ASA News

Navamedic Chairman Morten Jurs Boosts Stake, Signalling Insider Confidence

Navamedic ASA ( ($DE:N1A) ) has provided an announcement. Navamedic ASA’s chairman of the board, Morten Jurs, has increased his personal stake in the company by purchasing 28,001 shares through

3d agoN1A 0FDB

Navamedic Board Member Increases Stake with New Share Purchase

Navamedic ASA ( ($DE:N1A) ) just unveiled an update. Navamedic ASA board member Rune Wahl has increased his stake in the company by purchasing 10,000 shares at an average price

3d agoN1A 0FDB

Navamedic CEO Increases Stake with Insider Share Purchase

Navamedic ASA ( ($DE:N1A) ) has provided an update. Navamedic ASA has announced that its chief executive, Lars Minor, has purchased 13,000 company shares at an average price of NOK

3d agoN1A 0FDB

Navamedic Sets Out Financial Reporting Calendar for 2026–2027

Navamedic ASA ( ($DE:N1A) ) has issued an update. Navamedic ASA has published its financial reporting schedule for the remainder of 2026 and for 2027, outlining key dates for quarterly,

4d agoN1A 0FDB

Navamedic Boosts Margins as Q3 Revenue Falls on Weaker Drug and Consumer Health Sales

The latest announcement is out from Navamedic ASA ( ($DE:N1A) ). Navamedic reported third-quarter 2026 revenues of NOK 120.6 million, down 13.2% year on year as weaker sales in Prescription

4d agoN1A 0FDB

Navamedic Sets Webcast for Third-Quarter 2026 Results

Navamedic ASA ( ($DE:N1A) ) just unveiled an announcement. Navamedic ASA, a healthcare products supplier listed on the Oslo Stock Exchange, serves hospitals and pharmacies across the Nordics, Baltics and

1w agoN1A 0FDB

Navamedic Extends Nordic Rights to Obesity Drug Mysimba for Five Years

Navamedic ASA ( ($DE:N1A) ) has shared an announcement. Navamedic ASA, a Nordic-focused healthcare products provider headquartered in Oslo and listed on the Oslo Stock Exchange, distributes a wide range

1w agoN1A 0FDB

Navamedic COO Boosts Shareholding in Insider Trade Disclosure

Navamedic ASA ( ($DE:N1A) ) just unveiled an update. Navamedic ASA’s chief operating officer, Alexander Lidmejer, has increased his personal stake in the company by purchasing 6,905 shares at an

2M agoN1A 0FDB

Navamedic lifts margins on prescription drug growth despite one-off costs

Navamedic ASA ( ($DE:N1A) ) has shared an update. Navamedic ASA reported second-quarter 2026 revenues of NOK 140.3 million, up 2.2 percent year-on-year, with gross margin improving to 38.4 percent

2M agoN1A 0FDB

N1A Upcoming Earnings Report: What to Expect?

Navamedic ASA (N1A) is scheduled to report 2nd quarter earnings on 08/14/2026. Regarding Q2 estimates, Wall Street analysts expect Navamedic ASA to post earnings of -NOK0.02 per share. Revenue expectations

2M agoN1A 0FDB

0FDB FAQ

What was Navamedic ASA’s price range in the past 12 months?

Navamedic ASA lowest share price was kr 10.00 and its highest was kr 26.50 in the past 12 months.

What is Navamedic ASA’s market cap?

Navamedic ASA’s market cap is kr 267.39M.

When is Navamedic ASA’s upcoming earnings report date?

Navamedic ASA’s next earnings report is estimated for Feb 12, 2027 (not yet confirmed), which is in 102 days.

How were Navamedic ASA’s earnings last quarter?

Navamedic ASA released its earnings results on Oct 29, 2026. The company reported -kr 0.13 earnings per share for the quarter.

Is Navamedic ASA overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Navamedic ASA pay dividends?

Navamedic ASA does not currently pay dividends.

What is Navamedic ASA’s EPS estimate?

Navamedic ASA’s EPS estimate is 0.01.

How many shares outstanding does Navamedic ASA have?

Navamedic ASA has 23,981,379 shares outstanding.

What happened to Navamedic ASA’s price movement after its last earnings report?

Navamedic ASA reported an EPS of -kr 0.13 in its last earnings report. Following the earnings report the stock price went down -22.179%.

Which hedge fund is a major shareholder of Navamedic ASA?

Currently, no hedge funds are holding shares in GB:0FDB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Navamedic ASA

Navamedic ASA, an Oslo, Norway-based pharmaceutical firm established in 2002 and formerly known as Glucomed AS until its name change in 2004, operates across Northern Europe. The company is actively involved in the entire lifecycle of pharmaceutical and related goods, from development and manufacturing to their commercialization and distribution. Its comprehensive portfolio encompasses a diverse range of products, including prescribed and over-the-counter medications, specialized medical nutrition, medical devices, dietary supplements, and cosmetic items. A significant portion of its offerings is dedicated to medical nutrition, formulated to address various metabolic disorders such as phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders. These nutritional solutions also cater to conditions like glycogen storage diseases, renal diseases, fat metabolism issues, malnutrition, and support for ketogenic diets. Furthermore, Navamedic features a consumer health division providing non-prescription drugs and wellness products for common ailments including pain relief, coughs, colds, gastrointestinal issues, and women's health, primarily distributed through pharmacies and drugstores. The company also supplies specialty pharmaceuticals targeting specific therapeutic areas such as dermatology, wound care, women's health, urology, and obesity. Completing its product line are branded generics, notably in cardiology and antibiotics. Its widespread distribution network ensures products reach hospitals, individual patients, and retail pharmacies throughout its operational regions.

Navamedic ASA (0FDB) Earnings & Revenues

Historic Earnings Reports

Technical Analysis

Overall Consensus

Indicator	Bullish	Neutral	Bearish
Overall Consensus	4	2	15
Technical Analysis	4	2	3
Moving Averages	0	0	12

Technical Analysis >

Popular Stocks

Popular Stocks
Company	Price & Change	Follow
NVDANvidia
AAPLApple
MSFTMicrosoft

0FDB Stock Chart & Stats

Navamedic ASA News

Navamedic Chairman Morten Jurs Boosts Stake, Signalling Insider Confidence

Navamedic Board Member Increases Stake with New Share Purchase

Navamedic CEO Increases Stake with Insider Share Purchase

Navamedic Sets Out Financial Reporting Calendar for 2026–2027

Navamedic Boosts Margins as Q3 Revenue Falls on Weaker Drug and Consumer Health Sales

Navamedic Sets Webcast for Third-Quarter 2026 Results

Navamedic Extends Nordic Rights to Obesity Drug Mysimba for Five Years

Navamedic COO Boosts Shareholding in Insider Trade Disclosure

Navamedic lifts margins on prescription drug growth despite one-off costs

N1A Upcoming Earnings Report: What to Expect?

0FDB FAQ

Company Description

Navamedic ASA

Navamedic ASA (0FDB) Earnings & Revenues

Technical Analysis

Overall Consensus

Popular Stocks

Become an Expert with TipRanks Premium